Pharmacodynamic Effects When Clopidogrel is Given before Cangrelor Discontinuation

Journal of Interventional Cardiology

Volumn 28, Issue 5, 2015, Pages 415-419

  Schneider, David J ^a   Agarwal, Zubin ^a   Seecheran, Naveen ^a   Gogo, Prospero ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA1 INTEGRIN; CANGRELOR; CLOPIDOGREL; GLYCOPROTEIN IIIA; L SELECTIN; PADGEM PROTEIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DRUG PROTEIN BINDING; HUMAN; LOADING DRUG DOSE; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TIME TO TREATMENT; TREATMENT WITHDRAWAL; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DRUG EFFECTS; DRUG INTERACTION; FEMALE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; THROMBOCYTE;

ADENOSINE MONOPHOSPHATE; ADULT; AGED; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE;

EID: 84945460400     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12229     Document Type: Article

References (9)

1. Norgard NB, Cangrelor: A novel P2Y12 receptor antagonist. Expert Opin Investig Drugs 2009; 18: 1219-1230.
2. Steinhubl SR, Oh JJ, Oestreich JH, et al., Transitioning subjects from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534.
3. Dovlatova NL, Jakubowski JA, Sugidachi A, et al., The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008; 6: 1153-1159.
4. Bhatt DL, Stone GW, Mahaffey KW, et al., Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-1313.
5. Bhatt DL, Lincoff AM, Gibson CM, et al., Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
6. Harrington RA, Stone GW, McNulty S, et al., Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
7. Angiolillo DJ, Schneider DJ, Bhatt DL, et al., Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012; 34: 44-55.
8. Schneider DJ, Agarwal Z, Seecheran N, et al., Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv 2014; 7: 435-442.
9. Schneider DJ, Seecheran N, Raza SS, et al., Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis 2015; 26: 42-48.